Key Points
- CEO Christopher Kroeger sold 20,100 shares of Maplight Therapeutics on May 7 at an average price of $28.65, totaling $575,865. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and he still held 1,560,720 shares afterward.
- Maplight Therapeutics recently missed earnings estimates, reporting quarterly EPS of ($2.47) versus the consensus estimate of ($1.05). Analysts now expect the company to post -3.96 EPS for the current fiscal year.
- Wall Street sentiment remains mixed but generally positive, with a consensus rating of “Moderate Buy” and an average price target of $34.43. Several firms recently issued buy ratings, though one analyst downgraded the stock to sell.
Maplight Therapeutics, Inc. (NASDAQ:MPLT - Get Free Report) insider James Woodruff Lillie sold 721 shares of the stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $28.28, for a total transaction of $20,389.88. Following the sale, the insider owned 242,729 shares of the company's stock, valued at approximately $6,864,376.12. This represents a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
James Woodruff Lillie also recently made the following trade(s):
- On Wednesday, May 6th, James Woodruff Lillie sold 24,811 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.76, for a total transaction of $713,564.36.
- On Tuesday, May 5th, James Woodruff Lillie sold 11,095 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.20, for a total transaction of $312,879.00.
- On Monday, May 4th, James Woodruff Lillie sold 15,801 shares of Maplight Therapeutics stock. The stock was sold at an average price of $27.96, for a total transaction of $441,795.96.
Maplight Therapeutics Stock Up 9.8%
Shares of MPLT opened at $30.09 on Tuesday. Maplight Therapeutics, Inc. has a one year low of $12.24 and a one year high of $33.28. The business has a 50-day moving average of $23.27. The stock has a market capitalization of $1.28 billion and a price-to-earnings ratio of -0.76.
Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($2.47) EPS for the quarter, missing the consensus estimate of ($1.05) by ($1.42). Analysts anticipate that Maplight Therapeutics, Inc. will post -3.96 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several brokerages have commented on MPLT. Needham & Company LLC began coverage on shares of Maplight Therapeutics in a report on Wednesday, April 8th. They issued a "buy" rating and a $37.00 price objective for the company. Canaccord Genuity Group initiated coverage on shares of Maplight Therapeutics in a report on Thursday, March 19th. They issued a "buy" rating and a $35.00 price objective for the company. TD Cowen initiated coverage on shares of Maplight Therapeutics in a report on Tuesday, April 7th. They set a "buy" rating for the company. Weiss Ratings assumed coverage on shares of Maplight Therapeutics in a report on Thursday, January 22nd. They set a "sell (e)" rating for the company. Finally, HC Wainwright assumed coverage on shares of Maplight Therapeutics in a research report on Monday, May 4th. They set a "buy" rating and a $45.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $34.43.
Get Our Latest Report on MPLT
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Strs Ohio purchased a new position in shares of Maplight Therapeutics during the 4th quarter worth $53,000. Police & Firemen s Retirement System of New Jersey bought a new position in Maplight Therapeutics in the 4th quarter worth $70,000. New York State Common Retirement Fund purchased a new stake in Maplight Therapeutics in the 4th quarter worth $93,000. MetLife Investment Management LLC purchased a new stake in Maplight Therapeutics in the 4th quarter worth $172,000. Finally, Walleye Capital LLC purchased a new stake in Maplight Therapeutics in the 4th quarter worth $205,000.
About Maplight Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
